In T lymphocytes, the Wiskott-Aldrich Syndrome protein (WASP) and WASP-interacting-protein (WIP) regulate T cell antigen receptor (TCR) signaling, but their role in lymphoma is largely unknown. Here we show that the expression of WASP and WIP is frequently low or absent in anaplastic large cell lymphoma (ALCL) compared to other T cell lymphomas. In anaplastic lymphoma kinase-positive (ALK+) ALCL, WASP and WIP expression is regulated by ALK oncogenic activity via its downstream mediators STAT3 and C/EBP-β. ALK+ lymphomas were accelerated in WASP-and WIP-deficient mice. In the absence of WASP, active GTP-bound CDC42 was increased and the genetic deletion of one CDC42 allele was sufficient to impair lymphoma growth. WASP-deficient lymphoma showed increased mitogen-activated protein kinase (MAPK) pathway activation that could be exploited as a therapeutic vulnerability. Our findings demonstrate that WASP and WIP are tumor suppressors in T cell lymphoma and suggest that MAP-kinase kinase (MEK) inhibitors combined with ALK inhibitors could achieve a more potent therapeutic effect in ALK+ ALCL.
L
oss-of-function mutations in the WAS gene, which encodes WASP, causes Wiskott-Aldrich syndrome (WAS), a rare X-linked primary immunodeficiency of variable severity characterized by microthrombocytopenia, eczema, autoimmunity, recurrent infections and a predisposition to lymphoma development 1 . As WASP is selectively expressed in hematopoietic cells, the phenotype in patients with WAS is associated with defects in hematopoiesis and the immune system. WASP abundance in cells is regulated by WIP. WIP, encoded by the gene WIPF1, binds to the WH1 domain of WASP and protects WASP from degradation [2] [3] [4] [5] . The main regulator of WASP activation is the Rho family GTPase cell division cycle 42 (CDC42). In its GTP-bound state, CDC42 binds the GTPase-binding domain of WASP to release the verprolin homology domain-cofilin homology domain-acidic region autoinhibitory domain and to permit the binding to the actin-related protein-2/3 (ARP2/3) complex and actin nucleation 4, 6, 7 . Additional mediators, such as PIP2, and hematopoietic-specific kinases, such as BTK, LTK, FYN and NCK1, contribute to the activation of WASP 7, 8 . T lymphocytes from patients with WAS and WASP-and WIPdeficient mice show a number of defects, including defective proliferation in response to T cell receptor (TCR) stimulation, disturbed formation of surface projections, defective cytokine polarization and secretion, disrupted assembly of filamentous actin at the immunological synapse and impaired TCR-mediated signaling [7] [8] [9] [10] . Other cells of the adaptive immune system, such as B cells, as well as cells of the innate immune system, such as macrophages and dendritic cells, also have functional defects that have yet to be completely characterized 7, 11 . Importantly, WASP-dependent actin nucleation is essential for the formation of the immunological synapses in T cells and several other WASP-mediated phenotypes 4, 7 . Increasing evidence supports the concept that TCR-mediated signaling is also critical for the pathology of T cell lymphoma. Mutations in genes involved in TCR signaling, such as KRAS, RHOA, VAV1, CD28, FYN, LCK and PLCG1, are frequently found in T cell lymphomas that retain TCR expression, such as peripheral T cell lymphoma (PTCL-NOS) and angioimmunoblastic T cell lymphoma (AITL) 12 . By contrast, in ALCL, TCR signaling is typically lost and is bypassed by oncogenic tyrosine kinase signaling, most often secondary to aberrant activation of ALK, ROS1 or TYK2 [13] [14] [15] [16] . Recent discoveries have highlighted, among several pathways downstream of TCR signaling, the pathogenetic role of Rho GTPases, such as RAC1, CDC42 and RHOA, in T cell lymphoma 12 .
Inactivating or dominant negative mutations in RHOA are the
Wiskott-Aldrich syndrome protein (WASP) is a tumor suppressor in T cell lymphoma
Matteo Menotti 1, 13 , Chiara Ambrogio 2, 15 , Taek-Chin Cheong 3, 15 , Chiara Pighi 1, 3 , Ines Mota 1 
Articles
NATuRE MEDICINE most common recurrent genetic event in AITL and are also present in PTCL-NOS [17] [18] [19] . RAC1 and CDC42 genes are not recurrently mutated in lymphoma, yet they are activated by mutations of upstream GTP-exchange factors (GEFs), such as VAV1 and VAV3. VAV1 is frequently activated by mutations and translocations in PTCL 20 , whereas oncogenic ALK constitutively activates VAV1 and VAV3 in ALCL, thereby increasing RAC1 and CDC42 activity and promoting lymphoma survival [21] [22] [23] . Taken together, these studies indicate there is a critical role of downstream mediators of TCR signaling and Rho GTPases in T cell lymphoma. In this context, in contrast to the well-characterized function of WASP and WIP in normal TCR signaling, their role in T cell lymphoma is largely unknown.
We investigated WASP and WIP expression in a series of T cell lymphomas and found that WASP and WIP expression are selectively low or absent in ALCL but retained in lymphomas with conserved TCR signaling, such as PTCL-NOS and AITL. WASP or WIP deficiency significantly accelerated the development of ALK-driven lymphoma in mice by increasing active CDC42 and enhancing MAPK signaling. Reduction of CDC42 abundance by deletion of one copy of Cdc42 abrogated the acceleration of lymphomagenesis in WASP-deficient mice. Therapeutically, the forced re-expression of WASP impaired lymphoma growth, and MAPK inhibitors potentiated the effect of the ALK inhibitor crizotinib and exposed an enhanced vulnerability in ALK-driven lymphoma. Overall, these results indicate that WASP is a tumor suppressor in ALCL and highlight specific therapeutic susceptibilities.
Results

Selective low expression of WASP and WIP in ALCL.
To investigate the potential role of WASP and WIP in the ontogeny of T cell lymphomas, we analyzed WASP and WIP mRNA expression in a series of human T cell lymphomas, including AITL, PTCL-NOS, ALK+ and ALK-negative (ALK-) ALCL, which altogether account for more than 90% of T cell lymphomas 24 . ALK expression was confined to ALK+ ALCL, TNFSR8 (CD30) expression was enriched in ALCL; WASP, CDC42 and WASL (N-WASP) mRNA expression was similar in various subtypes of T cell lymphoma, whereas WIP mRNA was significantly lower in ALCL and lowest in ALK+ ALCL (Fig. 1a) . Considering that WIP regulates WASP stability, we investigated the expression of WASP and WIP proteins by immunohistochemistry in a series of T lymphomas. We found that expression of WASP and WIP was frequently low or negative in ALCL, but it was always retained in ; ALK+ ALCL versus ALK-ALCL, **P = 0.0075; significance was determined by unpaired, two-tailed Student's t-test). TNFRS8 (CD30) is strongly expressed in ALK-and ALK+ ALCL but not in other TCL subtypes. b, Representative H&E staining and immunohistochemistry stainings performed with the indicated antibody on human T cell lymphoma subtypes. The number of human T cell lymphoma samples analyzed is reported in Fig. 1c . WASP antibody was validated in formalin-fixed samples on samples with inducible WASP expression ( Supplementary Fig. 7f ). WIP antibody cross reacts with mouse WIP and was validated on WIP knockout cells ( Supplementary Fig. 1b) . Scale bar, 100 μ m. Insets: high-magnification images. c, WASP and WIP expression in human T cell lymphoma subtypes. AITL, n = 20; PTCL-NOS, n = 20; ALK-ALCL, n = 29; ALK+ ALCL, n = 43 for WASP and n = 31 for WIP; other TCL are natural killer (NK)/T cell lymphoma, nasal-type, n = 3 and hepatosplenic γ δ T cell lymphoma, n = 3. The number of patient samples is indicated for each lymphoma subtype. WASP and WIP expressions were quantified by immunostaining. Normal expression, expression equal to surrounding reactive T cells; low expression, decreased expression compared to surrounding reactive T cells; and no expression, absence of expression in lymphoma cells.
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AITL and PTCL-NOS as well as in other rare T cell lymphoma, such as natural killer (NK)/T cell lymphoma and γ δ hepatosplenic T cell lymphoma (Fig. 1b,c and Supplementary Fig. 1a,b) . Taken together, these data showed that WASP and WIP expression is selectively decreased in ALCL as compared to other T cell lymphomas.
WASP or WIP deficiencies accelerate T cell lymphoma development. WASP-deficient mice do not develop lymphoma spontaneously and have normal T thymic cell maturation, but they exhibit defective T cell activation 9 . To directly address the biological role of WASP and WIP in ALCL, we crossed NPM-ALK transgenic mice with Wasp −/− mice. The NPM-ALK fusion protein is the canonical and most frequent driver oncogene in ALCL, and NPM-ALK transgenic mice develop T cell lymphoma with high penetrance 25 . Fig. 1c ). The number of T cells and the pattern of , ****P < 0.0001; significance was determined by log-rank (Mantel-Cox) test. b, Western blot analysis from n = 3 independent primary lymphomas isolated from NPM-ALK transgenic mice crossed with WASP-deficient mice. The blot is representative of at least two independent experiments with similar results. Actin was used as a loading control. Uncropped blots are available in Supplementary Fig. 11 , **** P < 0.0001; significance was determined by log-rank (Mantel-Cox) test. d, Western blot analysis from n = 3 independent primary lymphomas isolated from NPM-ALK transgenic mice crossed with WIP-deficient mice. The blot is representative of at least two independent experiments with similar results. Actin was used as a loading control. Uncropped blots are available in Supplementary Fig. 11 . e, Representative H&E stain (left) and immunohistochemistry for Ki-67 (middle) and cleaved Caspase 3 (right), performed on NPM-ALK lymphoma with the indicated genotypes (n = 5 mice for each genotype). Scale bar, 100 μ m. Insets: high-magnification images. f,g. Quantification of Ki-67 (f) and cleaved caspase 3 (g) positive cells in NPM-ALK lymphoma with the indicated genotypes (n = 5 mice for each genotype). Data are shown as means ± s.d.; significance was determined by an unpaired, two-tailed Student's t-test.
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NATuRE MEDICINE thymic T cell development were comparable in NPM-ALK and NPM-ALK/Wasp −/− mice ( Supplementary Fig. 1d ,e). Remarkably, WASP deficiency significantly accelerated the onset of lymphomas and hastened mortality (Fig. 2a,b (Fig. 2e-g ). The similarity of the survival phenotype between WASP and WIP-deficient mice (Fig. 2a-c) is consistent with the near complete absence of WASP in WIP-deficient mice ( Fig. 2d) and is in keeping with the known role of WIP in WASP stability 3 . Heterozygous Wip +/− mice had intermediate levels of WASP and WIP expression as well as an intermediate survival phenotype, indicating that relative levels of WASP can contribute to the kinetics of lymphoma development. Overall, these data suggest that WASP deficiency probably bears responsibility for the phenotype in WIP-deficient mice. These results mirror the findings in human patients with WAS, in whom a complete absence of the protein is associated with a more profound phenotype, including a higher risk of lymphoma development, compared to patients that retain partial expression of WASP and present with milder phenotypes and a lower incidence of lymphoid malignancies 10, 28 . Oncogenic activity of NPM-ALK in lymphocytes controls actin polymerization via a direct activation of VAV1 and VAV3, which are GEFs for RAC1 and CDC42 21, 22 . Lymphocytes transformed by NPM-ALK are large and irregular (hence the term 'anaplastic' that collectively defines ALK-rearranged lymphoma), hypermotile and have accentuated cellular polarization due to polar assembly of actin filaments 21, 23 . Lymphomas that developed in NPM-ALK/ Wasp −/− or NPM-ALK/Wip −/− mice had a significantly smaller mean cellular diameter than NPM-ALK lymphoma cells ( Supplementary  Fig. 2a,b) . NPM-ALK/Wasp −/− or NPM-ALK/Wip −/− lymphoma cells also showed markedly decreased actin polarization ( Supplementary  Fig. 2a,c) , consistent with defects of actin nucleation and assembly associated with complete loss of WASP or WIP. In reverse experiments, doxycycline-inducible overexpression of WASP and WIP in human ALCL resulted in increased mean cellular diameter and actin polymerization ( Supplementary Fig. 2d ,e).
CDC42 mediates accelerated lymphoma development in WASPdeficient cells. To elucidate the mechanisms of accelerated lymphomagenesis in the absence of WASP, we characterized the expression profiles of NPM-ALK-Wasp −/− lymphomas ( Supplementary Fig. 3a) . Gene set enrichment analysis demonstrated that serum response factor pathway, known to be activated by Rho family GTPase signaling 29 , as well as other GTPase signatures, were significantly Fig. 3b-d (Fig. 3a) , indicating that the amount of active CDC42 is increased in cells that lack WASP. In addition to increased CDC42 activation, NPM-ALK/ Wasp −/− lymphomas also showed increased activation of the MAPK pathway as assessed by ERK1/2 phosphorylation (Fig. 3b) .
To assess directly whether CDC42 abundance was critical for lymphoma acceleration in WASP-deficient cells, we crossed NPM-ALK/ Wasp −/− mice with a conditional Cdcd42 lox allele; deletion of Cdc42 in T cells was accomplished by further crossing with CD4-Cre mice 23 . The deletion of one Cdc42 allele was associated with decreased protein abundance (Fig. 3c) 23 
, in NPM-ALK/Wasp
+/+ lymphoma only the biallelic deletion of Cdc42 induced impairment of lymphoma growth and apoptosis (Fig. 4c) . Altogether, these data demonstrate that WASP-deficient cells are exquisitely sensitive to the cellular abundance of CDC42.
Oncogenic ALK activity promotes WASP and WIP downregulation via STAT3 and C/EBP-β. To investigate WASP-and WIPdependent mechanisms of ALK+ ALCL lymphoma progression, we measured WASP and WIP expression in ALK cell lines and confirmed that in several cell lines they were lower than in normal T cells or other lymphoma types ( Fig. 5a and Supplementary Fig. 4a ). By contrast, N-WASP was not decreased in ALCL ( Supplementary  Fig. 5a ). WIP mRNA was lower in ALK+ ALCL cell lines than in other T cell lines or in T cells from normal donors, whereas WASP mRNA was more variable (Fig. 5b) . Overall, these patterns of gene expression in ALCL cell lines recapitulate the findings in primary ALCL from patients ( Fig. 1) .
As it is known that ALK oncogenic activity controls protein expression by transcriptional regulation or epigenetic silencing 30, 31 , we tested whether WASP and WIP expression were directly controlled Articles NATuRE MEDICINE by ALK activity. Knocking-down ALK expression with an inducible shRNA system 32 , led to increased WASP and WIP mRNA and protein expression (Fig. 5c,d ). Consistently, inhibition of ALK activity by the ALK inhibitors crizotinib and alectinib resulted in increased WASP and WIP mRNA expression (Fig. 5e) . Conversely, doxycycline-inducible expression of oncogenic ALK in ALK-negative lymphoma cells down-regulated the expression of both WASP and WIP ( Supplementary Fig. 5b ). Treatment of cells with azacitidine, which is known to restore expression of genes, such as LAT and ZAP70, that are repressed by ALK through methylation 30, 31 , did not change WASP and WIP expression ( Supplementary Fig. 5c,d ). Oncogenic ALK activates several downstream pathways, with STAT3 and C/ EBP-β representing key downstream effectors 16 . Knock-down of either STAT3 or C/EBP-β resulted in an increased WASP and WIP mRNA and protein levels ( Fig. 5f and Supplementary Fig. 5e-g ). Taken together, these data indicate that ALK oncogenic activity The blot is representative of three independent experiments with similar results. Actin was used as a loading control. Uncropped blots are available in Supplementary Fig. 11 . Mean protein expression of CDC42 in mouse cell lines that were treated with 4-OHT or were not treated (right). Data are shown as means ± s.d. from three independent experiments with similar results; significance was determined by an unpaired, two-tailed Student's t-test. b, Cell growth assay performed on lymphoma cell lines obtained from NPM-ALK transgenic mice with the indicated genotypes, transduced with Cre ERT2 and treated with 4-OHT. Measurements were taken at the indicated time points (n = 3 biologically independent samples). Data are shown as means ± s.e.m.; significance was determined by unpaired, two-tailed Student's t-test; n.s., not significant. c, Apoptosis analysis performed on lymphoma cell lines obtained from NPM-ALK transgenic mice with the indicated genotypes that were treated as in a. Measurements were taken at the indicated time points by TMRM staining and flow cytometry analysis. The percentage of dead cells was calculated above background (n = 3 independent experiments). Data are shown as means ± s.d.; significance was determined by unpaired, two-tailed Student's t-test.
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impairs WASP and WIP expression by a transcriptional repression mediated by STAT3 and C/EBP-β . To investigate if STAT3 and C/ EBP-β might directly regulate expression of WAS and WIPF1 genes, we performed chromatin immunoprecipitation and sequencing (ChIP-seq) on ALCL cell lines treated with crizotinib. As expected, 3 h of treatment with crizotinib blocked ALK phosphorylation that in turn resulted in a marked de-phosphorylation of STAT3 without affecting total STAT3 levels ( Supplementary Fig. 6a ). When ALK was active, STAT3 bound genome-wide, whereas in the presence of crizotinib STAT3 binding was almost completely abrogated throughout the genome (Fig. 5g and Supplementary  Fig. 6c ), including at loci proximal to both the WAS and WIPF1 genes (Fig. 5h,i) . In contrast, C/EBP-β bound to WAS and WIPF1 genes but its binding was not affected by ALK blockade (Fig. 5h,i and Supplementary Fig. 6b,c) . Remarkably, STAT3 and C/EBP-β binding sites co-localized with H3K4me3 and H3K27Ac marks indicating that they could functionally contribute to WASP and WIP expression (Supplementary Fig. 6d ). Thus, our results are consistent with a model by which STAT3 and C/EBP-β regulate WASP and WIP expression where STAT3 regulation directly depends on an ALK-mediated activation.
WASP and WIP abundance control lymphoma growth. As absence of WASP accelerates lymphoma growth in mouse models, we reasoned that decreased WASP and WIP expression could contribute also to the biology of human ALK+ ALCL. To test this hypothesis, we forcibly re-expressed WASP and WIP in ALCL cells by using a doxycycline-inducible lentiviral vector. Transduction with WASP vector alone did not increase WASP expression (data not shown), whereas transduction with WIP lentivirus induced a moderate increase in endogenous WASP ( Supplementary Fig. 7a ), confirming that the levels of WASP in ALCL are regulated by WIP as they are in normal T cells. When ALCL cells were co-transduced with both WASP and WIP lentiviruses, WASP expression was comparable to normal T cells (Fig. 6a) . On WASP and WIP induction, the GTP-bound form of CDC42 markedly decreased in ALCL cells, thus confirming that the WASP expression level regulates the abundance of active CDC42 also in human ALCL cell lines (Fig. 6b) . Next, we found that ALCL cell lines with induced WASP and WIP expression had impaired growth in vitro ( Supplementary Fig. 7b-d ) associated with an increased fraction of cells arrested in G1 phase of the cell cycle ( Supplementary Fig. 7e) . Consistently, the growth of ALCL mouse xenografts was significantly reduced when WASP and WIP expression was induced in vivo (Fig. 6c) . Induced expression of WASP in ALCL xenografts was associated with a significant increase in apoptosis and a decrease in proliferation (Fig. 6d,e and Supplementary Fig. 7f) . Furthermore, the activation of the MAPK pathway, as measured by phosphorylated ERK1/2 levels, decreased upon WASP and WIP induction, concomitant with an increase in cleaved caspase 3 ( Supplementary Fig. 4b) . Thus, the low expression of WASP and WIP contributes the pathogenesis of ALCL, and the restoration of their expression impairs lymphoma growth by decreasing the amount of active CDC42 and MAPK signaling.
MAPK activation is a therapeutic vulnerability in WASP-deficient lymphoma. Finally, we reasoned that increased MAPK signaling in ALCL cells expressing low levels of WASP could represent a therapeutic vulnerability. To test this concept, we treated lymphoma cells with trametinib, a MEK inhibitor approved for melanoma treatment and currently in trial for lymphoma (NCT00687622). Lymphomas from NPM-ALK/Wasp −/− mice were more sensitive than wild-type lymphoma to trametinib (Fig. 6f) as well as to additional MEK inhibitors (selumetinib, MEK162 and PD0325901) ( Supplementary  Fig. 8a ). Consistently, human ALCL with low WASP expression (SU-DHL1 and JB6) were also more sensitive than ALCL with higher WASP expression (TS and L82) ( Supplementary Fig. 8b ). Considering that ALK inhibitors have potent clinical activity in ALK+ ALCL 16, 33 , we also investigated whether MEK inhibition could potentiate ALK inhibitors in a combination therapy, as has been recently suggested for ALK-rearranged lung cancer 34 . In vitro, NPM-ALK lymphoma lines were sensitive to crizotinib, and the combination with trametinib further potentiated crizotinib activity ( Supplementary Fig. 8c ). In vivo, trametinib alone did not have an effect against NPM-ALK lymphoma, as expected from similar experiment in ALK+ lung cancer 34 . In contrast, the combination of trametinib with crizotinib was more potent than crizotinib alone for the treatment of NPM-ALK/Wasp −/− but not wild-type lymphoma (Fig. 6g) , supporting the concept that the MAPK pathway is a therapeutic vulnerability in WASP-deficient lymphoma.
Lymphocytes from patients with WAS show increased CDC42 activity and MAPK signaling. Patients with WAS have a variety mutations in the WAS gene that result in a variably reduce abundance or function WASP 7 . As in human ALCL and mouse models, the reduced or absent expression of WASP increases the abundance of active CDC42, and so we reasoned that lymphocytes from patients with absent or very low WASP expression should display higher CDC42 activation than control lymphocytes. We characterized Epstein-Barr virus (EBV)-immortalized B lymphocytes from three patients with WAS with defined WAS mutations (Supplementary Supplementary Fig. 11 . e, qRT-PCR expression analysis of WASP and WIP mRNA on three representative ALK+ ALCL human cell lines (TS, JB6 and Karpas-299) treated with two different ALK inhibitors, alectinib (30 nM) and crizotinib (100 nM) for 12 h (JB6 and Karpas-299) or 24 h (TS) (n = 3 independent experiments). Data are shown as means ± s.d.; significance was determined by an unpaired, two-tailed Student's t-test. f, qRT-PCR expression analysis of WASP and WIP mRNA on the ALK+ TS cell line in which the expression of STAT3 has been knocked down by the specific shRNA. The corresponding western blot of the shRNA knockdown is shown on the left. Two independent shRNA have been used for each knockdown assay (indicated with numbers 1 and 2). A scrambled shRNA has been used as control (n = 3 independent experiments). Data are shown as means ± s.d.; significance was determined by an unpaired, two-tailed Student's t-test. The blot is representative of three independent experiments with similar results. Actin was used as a loading control. Uncropped blots are available in Supplementary Fig. 11 . g, Heatmaps (left) and metaplots (right) of global STAT3 peaks obtained by ChIP-seq in SU-DHL1 cells treated for 3 h with crizotinib (300 nM). h,i, STAT3 or C/EBP-β ChIP-seq tracks at WAS (h) and WIPF1 (i) genes on two representative ALK+ ALCL human cell lines (JB6 and SU-DHL1) treated for 3 h with crizotinib (300 nM). The experiment was performed once on two independent cell lines with similar results. Fig. 9a ) and low or absent WASP expression ( Supplementary  Fig. 9b ). Indeed, lymphocytes from patients with WAS showed higher levels of CDC42 activation than control cells ( Supplementary  Fig. 9c ), in keeping with observations in NPM-ALK lymphoma cells. In addition, WAS lymphocytes showed decreased phosphorylation of STAT3 and AKT, consistent with defective cytokine production in WASP-deficient lymphocytes 35 , but they showed higher levels of ERK and S6 phosphorylation, consistent with increased activation of the MAPK pathway (Supplementary Fig. 9b ). These data show that lymphocytes from patients with WAS with absent WASP expression have higher activity of CDC42 and MAPK signaling, suggesting the possibility that the predisposition of patients with WAS to lymphoma could be associated to an intrinsic aberrant signaling in their lymphocytes. 10 . In this work, we provide evidence that WASP is an oncosuppressor in T lymphocytes, and we identify ALCL as a specific subtype of T cell lymphoma in which WASP and WIP expression is selectively downregulated and contributes to lymphoma pathogenesis. An interesting expansion of this work would be to study WASP and WIP expression in B cell lymphoma or other hematologic malignancies. Furthermore, we provide evidence that the levels of the Rho GTPase CDC42 are essential for the tumorsuppressor functions of WASP. The acceleration of lymphoma development in Wasp −/− mice was dependent on the abundance of CDC42 in lymphoma cells; Wasp −/− lymphomas had significantly higher amount of active GTP-bound CDC42 and a reduction of about half CDC42 protein was sufficient to revert the phenotype in vitro and in vivo (Fig. 3d and Fig. 4b,c) . Similar WASP-dependent regulation of active CDC42 was found in human ALCL (Fig. 6b) as well as in immortalized B lymphocytes from patients with WAS ( Supplementary Fig. 9c ), demonstrating that active CDC42 accumulates in normal and tumor lymphocytes in the absence of WASP.
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Considering the known role of WASP and WIP in T cell activation, we evaluated the possibility that the accelerated lymphoma development observed in WASP-and WIP-deficient mice could be associated to a defective immunosurveillance. However, several findings suggest that defective immunosurveillance is not sufficient to explain the accelerated lymphomagenesis in WASP-and WIP-deficient mice. Fig. 10a ) and defective MAPK pathway activation ( Supplementary Fig. 10b ) similar to Wasp −/− T cells, yet the loss of one copy of Cdc42 is sufficient to revert the lymphoma acceleration observed in Wasp −/− mice (Fig. 3d) Supplementary Fig. 10c ). Finally, experiments in human ALCL clearly show that the cellular levels of WASP and WIP intrinsically contribute to lymphoma growth in vitro and in vivo.
We showed that WASP and WIP expression are selectively decreased in ALCL, a subtype of T cell lymphoma that can be driven by translocations involving the ALK gene in ALK+ ALCL or by translocations involving other tyrosine kinases or phosphatases in ALK− ALCL 14, 15 . Interestingly, aberrant STAT3 activation is frequent in both ALK+ and ALK− ALCL where STAT3 phosphorylation is directly controlled by ALK or other oncogenic tyrosine kinases, such as ROS1 and TYK2 14, 36 . We showed that ALK oncogenic activity mediates downregulation of WASP and WIP through a STAT3 and C/EBP-β dependent transcriptional repression. ChIP-seq experiments showed that abrogation of STAT3 activation by ALK inhibitors resulted in a profound genome-wide loss of STAT3 binding as well as that at WAS and WIPF1 genes (Fig. 5g-i and Supplementary Fig. 6b ,c) Therefore, WASP and WIP downregulation could represent a common feature of T cell lymphomas where the activity of STAT3 predominates, typically those induced by deregulated tyrosine kinases such as ALCL. In contrast, AITL and PTCL are more dependent on a tonic TCR signaling that relies on the maintenance of cytoskeletal signaling functions in which WASP and WIP are essential. However, TCR ligation induces WASP degradation that in turn modifies assembly of F-actin. Thus, reduced levels of WASP after TCR engagement could also play a role in downstream signaling in normal T cells 37 .
Other mechanisms may contribute to the downregulation of WASP or WIP in ALCL. For example, a recent study showed that NPM-ALK directly phosphorylates Tyr102 of WASP; this phosphorylation impairs the binding of WASP to WIP and increases proteasome-dependent WASP degradation 38 , overall confirming that ALK downregulates WASP expression by multiple mechanisms. In contrast to our findings, however, this study concluded that WASP contributes to the oncogenic activity of ALK. This discrepancy probably originates from a different approach that focused on abrogating the residual WASP expression by shRNA rather than investigating the overall low levels of WASP in ALCL.
Whereas WAS and WIPF1 mutations in ALCL have not been systematically studied, interestingly somatic loss of function (WAS G229E ) or frame-shift mutations (WAS G333fs and WAS
P329fs
) leading to premature WASP truncation similar to patients with WAS have been detected in 4.6% of PTCL-NOS 19 , raising the intriguing possibility that a fraction of other T cell lymphomas rely on somatic inactivation of WASP. In an ongoing effort to characterize WAS and WIPF1 genes in ALCL, we performed whole-exome sequencing in six cases of ALK+ ALCL. No somatic mutations of the WAS, WIPF1 and CDC42 genes were found, but deletions of chromosome X in the region containing the WAS gene was detected in two out of six cases, suggesting that gene deletion could be an additional mechanisms for WASP inactivation in ALCL. Furthermore, we found one case with a mutation of the intersectin 2 (ITSN2) gene and two cases with mutations of the Myosin Heavy Chain 8 (MYH8) genes (Supplementary Table 1 ). ITSN2 is a GEF for CDC42 and regulates its activation 39 and interacts directly with WASP
40
. MYH8 is associated with the PAK and GTPase pathways. Interestingly, this gene was recently found also mutated in ALK− ALCL 14 . These are limited observations that need to be expanded in larger series of cases but could underlie additional potential mechanisms that alter the CDC42-WASP axis in T cell lymphoma.
Taken together, it is tempting to propose that T cell lymphomas can be divided into two main categories. In T cell lymphomas that retain TCR signaling dependence, such as PTCL-NOS and AITL, WASP and WIP functions are maintained, at least initially, as they are key molecules for the immunological synapse and TCR signaling; once a lymphoma is established, inactivating mutations of WASP could be further selected by providing additional growth advantage. On the other hand, in T cell lymphomas that lost TCR signaling and depend on aberrant tyrosine kinase activity, such as ALCL, WASP and WIP are lost or downregulated as they act as tumor suppressors; their downregulation provides a biological advantage by increased active CDC42 and MAPK signaling. In these lymphomas, the hyperactivated MAPK pathway could represent an actionable therapeutic vulnerability when combined with the inhibition of ALK, which is the driver oncogene in ALK+ ALCL. Thus, inhibition of both ALK and MEK inhibitors could represent a more powerful therapeutic strategy in ALK+ ALCL, possibly for those patients who respond poorly to crizotinib 33 . A similar concept has been recently suggested for ALK+ lung cancers 34 .
In conclusion, by combining genetic and functional assays we have demonstrated an unexpected role for WASP and WIP as oncosuppressor proteins in lymphomas. Mechanistically, we have shown that the levels of CDC42 activation are increased in the absence of a binding to WASP, leading to increased proliferation and survival of lymphoma cells. The activation of CDC42 and MAPK pathway provides a therapeutic vulnerability in lymphoma with low WASP expression.
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Methods
Transgenic mice and tumor xenografts. CD4-NPM-ALK
CD4-NPM-ALK, Wasp
−/− and Wip −/− mice were bred in C57BL/6 background. NSG immunocompromised mice were purchased from Charles River Laboratories. For subcutaneous xenografts, human ALCL cell lines transduced with inducible lentiviral vectors expressing WASP and WIP complimentary DNA were injected in both flanks of NSG mice; 5 × 10 6 cells were resuspended in 150 µ l PBS and injected. Injected mice were administered drinking water containing doxycycline (1 mg ml −1 ) (Sigma) to express WASP and WIP cDNA. Tumor growth was measured with a caliper every two days. Mice were euthanized at humane endpoint, and tumors were resected with a scalpel and snapped frozen or paraffin fixed in buffer neutral formalin for further experiments.
Mice were treated with trametinib (1.5 mg kg −1 ) or crizotinib (30 mg kg
) or a combination of the two inhibitors by oral gavage once a day for a week. Tumor growth was measured with a caliper every two days. Both drugs were dissolved in 0.5% methylcellulose + 0.05% Tween-80. Mice were euthanized at humane endpoint.
Lymphoma cell lines obtained from NPM-ALK transgenic mice were injected subcutaneously in both flanks of syngeneic C57BL/6 or NSG mice, and 10 × 10 6 cells were resuspended in 150 µ l PBS and injected. Tumor growth was followed as described above.
Mice were handled and treated in accordance with European Community guidelines under the mouse protocol approved by the Italian Ministry of Research (no. 254/2017-PR). Immortalized EBV-transformed B lymphoblastoid cell lines were obtained from healthy controls and patients with WAS (enrolled in clinical protocol 04-09-113R) as previously described 42 and cultured in RPMI 1640 medium (Thermo Fisher Scientific) supplemented with 10% FBS, 2% penicillin, streptomycin 5 mg ml −1 (Gibco) and 1% glutamine (Gibco). Murine lymphoma cell lines were obtained from transgenic mice with the corresponding genotype. Briefly, at the humane endpoint mice were euthanized and tumoral thymuses were resected. Single-cell suspensions were prepared from fresh tumoral thymuses with mechanical disgregation and were isolated by using 40-μ m nylon cell strainer (BD Biosystems). Cells were grown in RPMI and cultured for at least 4 weeks before proceeding with further experiments.
Virus preparation and cell transduction. Lentiviruses were produced using the third-generation production system. Briefly, 293T cell lines were cultured in DMEM with 10% FBS. Cells at 70% confluency were co-transfected with pVSVG, pCMVR8.74, pRSV-Rev and a lentiviral vector expressing the construct of interest. Medium was replenished 12 or 18 h after transfection, and the supernatant was collected after 24 and 48 h. Collected supernatants were filtered through a 0.22-μ m filter, concentrated by ultracentrifugation (× 50,000g for 2 h) and resuspended in 500 μ l of sterile PBS. For infection, 5 × 10 4 cells were infected with the prepared lentivirus along with polybrene (8 μ g ml ), and cells with viral particles were spun down at 2,500 r.p.m. for 90 min and then incubated at 37 °C overnight.
STAT3-and C/EBP-β -specific shRNAs and inducible ALK shRNA have been previously described 43, 44 . Human Flag-WASP and Flag-WIP cDNA were obtained from A. Galy (Institut Gustave Roussy) and from Addgene, respectively. For the doxycycline-inducible system (Tet-ON), WASP and WIP cDNA were cloned into a modified pCCL vector as previously described 45 . SU-DHL1, JB6, DEL and Karpas-299 cell lines were co-infected with pCCL and rtTA plasmids. For cell-sorting enrichment, cells were induced with 1 μ g ml doxycycline for 12 h and sorted for GFP expression on a MoFlo High-Performance Cell Sorter (DAKO Cytomation).
Retroviruses were generated by transfection of pWZL Blast vector expressing CRE-ERT2 in 293 Phoenix packaging cells. Transfected cells were incubated at 37 °C for 12 or 18 h, and supernatants containing viral particles were collected at 24 and 48 h. 300 µ l retroviral supernatants were used to transduce 5 × 10 4 lymphoma cells as previously described 23 . CRE-ERT2-transduced cells were selected using blasticidin (Calbiochem) at 25 µ g ml −1 for 6 days.
Cell lysis and immunoblotting. Total cellular protein was extracted with GST-FISH buffer (10 mM MgCl 2 , 150 mM NaCl, 1% NP40, 2% glycerol, 1 mM EDTA, 25 mM HEPES pH 7.5), added with 1 mM phenylmethylsulfonyl fluoride, 10 mM NaF, 1 mM Na 3 VO 4 and protease inhibitors (Roche). Total cell lysate was cleared by centrifugation (13,000 r.p.m.) at 4 °C in a microcentrifuge for 10 min and quantified using the Bio-Rad protein assay method. Protein samples were normalized based on protein concentration, denaturated by addition of Laemmli buffer and boiled for 10 min. Thirty to fifty micrograms of proteins were run on sodium dodecyl sulfate-polyacrylamide gel electrophoresis under reducing conditions and transferred to nitrocellulose (GE Healthcare). Membranes were incubated with specific antibodies, detected with peroxidase-conjugated secondary antibodies (GE Healthcare) and enhanced using chemiluminescent reagent (Amersham).
The following primary antibodies were used: anti-ALK (Invitrogen, Catalog no. 35 Histology, immunohistochemistry and immunofluorescence. For histology, tissue samples were formalin-fixed and paraffin embedded, cut into 4-μ m-thick sections and stained with H&E.
For immunohistochemistry, formalin-fixed sections were de-waxed in xylene and dehydrated by passage through graded alcohols to water; sections were microwaved in citrate buffer pH 6 for 15 min and then transferred to PBS. Endogenous peroxidase was blocked using 1.6% hydrogen peroxide in PBS for 10 min followed by washing in distilled water. Normal serum diluted to 10% in 1% bovine serum albumin (BSA) was used to block nonspecific staining.
The slides were than incubated for 1 h with the following primary antibodies: anti-WASP (Epitomics), anti-WIP (Clone:H-224, Santa Cruz Biotechnology), anti-ALK (Clone: 18-0266, Zymed); anti-cleaved caspase 3 (Cell Signaling Technology), anti-murine Ki-67 (AbCam, Clone:SP6, Catalog no. ab16667) and anti-human Ki-67 (DAKO, Clone:MIB-1, Catalog no. M7240). After washing, sections were incubated with biotinylated secondary goat antibody to rabbit IgG and visualized with the EnVision system (Dako).
For immunofluorescence, cells were plated on glass coverslips pretreated with fibronectine (10 μ g ml −1 PBS) at 37 °C for 1 h and incubated overnight in fresh medium. Samples were fixed in 4% paraformaldehyde at room temperature for 10 min and permeabilized with 0.3% Triton X-100 for 5 min. Coverslips were incubated with 3% BSA for 1 h at room temperature and then stained with phycoerythrin-conjugated phalloidin (1/500, Sigma) and HOECHST (300 ng ml −1 , Sigma). Coverslips were mounted on microscope slides using anti-fading solution and viewed using a Leica photomicroscope. Images were acquired at room temperature by means of HCX PL APO × 100/1.40 OIL (Leica, Heidelberg, Germany) and analyzed by DM LM Leica software. Cell dimension has been measured using ImageJ software.
The slides were reviewed by experienced hematopathologists, and quantification of the levels of WASP and WIP expression was performed selectively in multiple areas where lymphoma cells were clearly enriched. This selection was achieved by comparing the areas on serial sections stained with the following markers: ALK for ALK+ ALCL, CD30 for ALK− ALCL, CD10 for AITL. When a marker was not available (such as loss of a particular T cell antigen) for PTCL-NOS, NK/T cell lymphoma and hepatosplenic γ δ T cell lymphoma, the selection of the areas with enriched lymphoma cells was based on morphologic criteria, such as a cluster of atypical cells or invasion of specific structures such as vessels in NK/T cell lymphoma or sinusoids in hepatosplenic γ δ T cell lymphoma. The quantification of WASP and WIP expression levels was achieved by comparison with an internal control constituted by normal B and T lymphocytes.
qRT-PCR analysis. Total RNA was extracted from cells using TRIzol solution (Invitrogen), followed by cDNA preparation from 1 µ g of total RNA. cDNA T cell purification, ex vivo activation and proliferation analysis. Untouched T cells were isolated from spleens of WASP-and WIP-deficient mice and wild-type mice by immunomagnetic depletion of B cells, monocytes/macrophages, natural killer cells, dendritic cells, erythrocytes and granulocytes.
Briefly, spleens were collected, placed on ice, washed in PBS to remove residual blood, cut into small pieces, crushed and physically dissociated using a Falcon cell strainer and subjected to hypotonic lysis of erythrocytes. Cells were resuspended in isolation buffer (PBS supplemented with 0.1% BSA and 2 mM EDTA). All non-T cells were depleted with a mixture of rat monoclonal IgG antibodies against non-T cells (' Antibody mix': anti mouse CD45R, CD11b, Ter-119 and CD16/CD32; Invitrogen) combined with Mouse Depletion Dynabeads (4.5 μ m diameter beads coated with a polyclonal sheep anti-rat IgG antibody; Invitrogen) following the manufacturer's instructions.
Isolated mouse T cells, bead-and antibody-free, were activated by adding Dynabeads Mouse T-Activator CD3/CD28 (polyclonal activation; Invitrogen).
For T cell proliferation analysis, purified and activated T cells (1 × 10 6 cells) were plated in a six-well plate and cultured at 37 °C in RPMI 1640 medium supplemented with 15% FBS, 2% penicillin, streptomycin 5 mg ml −1 and 50 mM 2-mercaptoethanol for 48 h. Cells were then collected for CellTiter-Glo analysis (Promega) following the manufacturer's instructions. Corresponding author(s): Roberto Chiarle Life Sciences Reporting Summary Nature Research wishes to improve the reproducibility of the work that we publish. This form is intended for publication with all accepted life science papers and provides structure for consistency and transparency in reporting. Every life science submission will use this form; some list items might not apply to an individual manuscript, but all fields must be completed for clarity.
For further information on the points included in this form, see Reporting Life Sciences Research. For further information on Nature Research policies, including our data availability policy, see Authors & Referees and the Editorial Policy Checklist.
Please do not complete any field with "not applicable" or n/a. Refer to the help text for what text to use if an item is not relevant to your study. For final submission: please carefully check your responses for accuracy; you will not be able to make changes later.
Experimental design 1. Sample size
Describe how sample size was determined.
In the transgenic mice experiment more than 30 mice for each genotype has been used. This large number of mice was achieved in several years of breeding. The only exception was the NPM-ALK, WASP-/-CDC42f/f, CD4-CRE genotype that showed short lifespan and therefore was not useful to determine lymphoma incidence. No sample size calculation was predermined. All mice were bred to perform various experiments required by the project and survival curves were then calculated by collecting the total number of mice for each genotype.
Data exclusions
Describe any data exclusions.
Each mouse was evaluated by autopsy for lymphoma. Mice that died for other causes without evidence of lymphoma were excluded from survival curves. No exclusion criteria were pre-established.
Replication
Describe the measures taken to verify the reproducibility of the experimental findings. 
Randomization
Describe how samples/organisms/participants were allocated into experimental groups.
All mice were randomly allocated in each group. For WASP deficient mice, because WASP is on the X chromosome, WASP-/-females and WASP-/ males were equally distributed between experimental groups.
Blinding
Describe whether the investigators were blinded to group allocation during data collection and/or analysis.
No blinded group allocation was used during the experiment procedures. Blinding was not relevant to this study as each experiment was associated with proper controls. For xenografts experiments with human lymphoma, for ethical reason the minimum number of mice to provide statistical values was determined based on previous experimental data and published articles.
Note: all in vivo studies must report how sample size was determined and whether blinding and randomization were used. nature research | life sciences reporting summary November 2017
Statistical parameters
For all figures and tables that use statistical methods, confirm that the following items are present in relevant figure legends (or in the Methods section if additional space is needed).
n/a Confirmed The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement (animals, litters, cultures, etc.)
A description of how samples were collected, noting whether measurements were taken from distinct samples or whether the same sample was measured repeatedly A statement indicating how many times each experiment was replicated
The statistical test(s) used and whether they are one-or two-sided For manuscripts utilizing custom algorithms or software that are central to the paper but not yet described in the published literature, software must be made available to editors and reviewers upon request. We strongly encourage code deposition in a community repository (e.g. GitHub). Nature Methods guidance for providing algorithms and software for publication provides further information on this topic.
Materials and reagents
Policy information about availability of materials 8. Materials availability Indicate whether there are restrictions on availability of unique materials or if these materials are only available for distribution by a third party.
Mouse models and primary derived cells lines of all genotypes are available for distribution without restrictions.
b. Describe the method of cell line authentication used.
Stock of cells lines were immediately generated after purchase. For experiments, cell lines were never kept for more than 3 consecutive months in culture, if needed for longer time a new stock was used. For some cells lines we also further authenticated them by sequencing of the mutations present in the p53 gene which are unique for each NPM-ALK cell line.
c. Report whether the cell lines were tested for mycoplasma contamination.
Cell lines were tested for mycoplasma monthly. If cells resulted positive for contamination, they were treated with mycoplasma removal agents until three consecutive PCR tests were negative.
d. If any of the cell lines used are listed in the database of commonly misidentified cell lines maintained by ICLAC, provide a scientific rationale for their use.
No commonly misidentified cell lines has been used Animals and human research participants
Policy information about studies involving animals; when reporting animal research, follow the ARRIVE guidelines
Description of research animals
Provide all relevant details on animals and/or animal-derived materials used in the study.
All the animals in the studies are mice, all the transgenic mice were maintained in C57BL/6 background; male and female mice were randomly selected. Primary lymphoma cell lines with different genotypes were immortalized from mice spontaneously without any type of genetic manipulation. Pre-tumoral thymuses were collected from 4-6 weeks old mice; tumoral thymuses were collected from 12-16 weeks old mice.
For xenograft experiments NSG immunocompromised mice were used. Mice of 8 ± 2 weeks of age and randomly sorted by sex were used.
